Neuralink Demonstrates Thought-Controlled Wheelchair Steering for Paralyzed Patients

How the N1 Implant Decodes Movement Intentions

The N1 Implant is an intracortical brain-computer interface that records neural signals from motor cortex neurons via 1,024 electrodes distributed across 64 ultra-thin threads . When a participant thinks about moving — for example, intending to push a joystick left or right — the implant detects the corresponding spiking patterns in motor cortex .

These neural signals are wirelessly transmitted to a custom Neuralink app running on a connected device, which decodes the intention in real time and translates it into digital commands (forward, reverse, steer, seat adjust) that the wheelchair executes . According to Neuralink, the system works by moving an on-screen cursor: move the cursor up and the wheelchair goes forward; down, backward; left and right to steer; the farther the cursor is pushed, the faster the chair moves . The system is calibrated to each individual's neural "vocabulary," so the participant does not need to physically move any muscles — thinking about the movement is sufficient .

The PRIME Study: Clinical Trial Context and Enrollment Milestones

The PRIME Study (Precise Robotically IMplanted Brain-Computer InterfacE, NCT06429735) is a first-in-human, single-arm, multi-site feasibility trial evaluating the safety and initial functionality of the N1 Implant and the R1 surgical robot in adults with quadriplegia from spinal cord injury or amyotrophic lateral sclerosis (ALS) .

Key enrollment and surgical milestones:

• First human implant: January 2024 — participant Noland received the first N1 implant .
• May 2023: The U.S. FDA cleared Neuralink's Investigational Device Exemption (IDE), authorizing the start of the PRIME Study .
• September 2023: Recruitment opened for the trial .
• 21 participants enrolled globally as of January 2026 (up from 12 in September 2025), across U.S. sites in Arizona and Florida, plus international sites . The U.K. arm (GB-PRIME) reached 7 patients by December 2025, with surgeries performed at UCLH's National Hospital for Neurology and Neurosurgery .
• Zero serious device-related adverse events have been reported through early 2026 .
• The study also enables participants to control computers, type, create art, and now steer powered wheelchairs .
• No peer-reviewed human trial data had been published by Neuralink as of mid-2026; current performance claims are based on company demonstrations, not independent replication .

Current Regulatory Status: Investigational Only, Not Approved

The N1 Implant is an investigational device only, not approved for commercial sale or general use .

• May 2023: The U.S. FDA granted Neuralink an Investigational Device Exemption (IDE) to conduct the PRIME Study — this is an authorization to run a clinical trial, not a market approval .
• Breakthrough Device Designation: The FDA also granted the N1 Implant "Breakthrough Device" status, which expedites development and review but does not constitute approval .
• Current phase: The N1 remains in an FDA-regulated IDE clinical stage (PRIME feasibility study) . As of mid-2026, no permanently implanted brain-computer interface from any company (Neuralink, Synchron, or Precision) has received FDA premarket approval .
• The device cannot be legally sold, prescribed, or implanted outside of the clinical trial enrollment criteria .

In short, Neuralink's wheelchair demonstration is a proof-of-concept within a carefully controlled clinical trial. The technology works for PRIME Study participants, but the N1 Implant is years away from potential commercial availability, pending successful trial completion, peer-reviewed data, and eventual FDA review .